Evidence map›Paper›PMID 38519820›Full record

Trial reportInternational journal of hematology2024

End-of-treatment 18[F]-FDG PET can predict early progression in patients receiving bendamustine-rituximab for follicular lymphoma in first relapse: a prospective West Japan hematology Study Group (W-JHS) NHL01 trial.

Koji Kato, Koji Izutsu, Momoko Nishikori, Hirohiko Shibayama, Yoshinobu Maeda, Kenichi Yoshimura, Ukihide Tateishi, Toshihiro Miyamoto, Yasufumi Matsuda, Jun Ishikawa and 7 more

Abstract readMulticenter StudyClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 1 country.

Koji KatoDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. kato.koji.429@m.kyushu-u.ac.jp.ORCID http://orcid.org/0000-0002-5815-4585
Koji IzutsuDepartment of Hematology, Toranomon Hospital, Tokyo, Japan.
Momoko NishikoriDepartment of Hematology/Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hirohiko ShibayamaDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Yoshinobu MaedaDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Kenichi YoshimuraInnovative Clinical Research Centre, Kanazawa University Graduate School of Medicine, Kanazawa, Japan.
Ukihide TateishiDepartment of Diagnostic Radiology, Tokyo Medical and Dental University, Tokyo, Japan.
Toshihiro MiyamotoDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Yasufumi MatsudaCancer Care Promotion Center, University of Fukui Hospital, Fukui, Japan.
Jun IshikawaDepartment of Hematology, Osaka International Centre Institute, Osaka, Japan.
Shinya RaiDepartment of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka, Japan.
Tsutomu TakahashiDepartment of Hematology, Shimane University Hospital, Shimane, Japan.
Takahiro YamauchiDepartment of Hematology and Oncology, University of Fukui, Fukui, Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osaka, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Yuzuru KanakuraDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan.
Junji SuzumiyaDepartment of Hematology, Koga Community Hospital, Daikakuji 2-30-1, Yaizu, Shizuoka, 425-0088, Japan. junji8suzumiya@gmail.com.
Kyushu University · JPKindai University · JPThe University of Osaka · JPKanazawa University · JPKoga Hospital · JPKyoto University · JPOkayama University Hospital · JPOsaka International Cancer Institute · JPShimane University Hospital · JPTokyo Medical and Dental University · JPToranomon Hospital · JPUniversity of Fukui · JPUniversity of Fukui Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Response determined by 18[F]-fluoro-2-deoxy-D-glucose (

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideDisease ProgressionFluorodeoxyglucose F18Lymphoma, FollicularPositron-Emission TomographyRituximabAdultAgedAged, 80 and overFemaleHumansJapanMaleMiddle AgedProspective StudiesBendamustine HydrochlorideFluorodeoxyglucose F18RadiopharmaceuticalsRituximabBendamustineFDG–PETFollicular lymphomaPredictive factorRituximab

Identifiers

PMID38519820
OpenAlexW4393066575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.